Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | MK-0616 - (CORALreef Lipids) | Low-density lipoprotein (LDL) cholesterol reduction | Phase 3 | Data Released | Oral | Cardiology |
| Merck & Company Inc. | WELIREG - (LITESPARK-005) | Advanced renal cell carcinoma (RCC) | Phase 3 | Data Released | oral | Oncology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) - (KEYNOTE-756) | High-Risk, Early-Stage ER+/HER2- Breast Cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | V116 - (STRIDE-6) | Pneumococcal Conjugate Vaccine | Phase 3 | Data Released | Intramuscular | Immunology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) combined with chemotherapy - (KEYNOTE-585) | Locally advanced resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) in combination with trastuzumab - (KEYNOTE-811) | HER2-positive gastric or Gastroesophageal junction (GEJ) adenocarcinoma | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | Ensifentrine - (ENHANCE - China) | Chronic obstructive pulmonary disease (COPD) | Phase 3 | Ongoing | Inhalation | Respiratory |
| Merck & Company Inc. | KEYTRUDA plus LENVIMA versus regorafenib - (LEAP-017) | Colorectal cancer | Phase 3 | Intravenous and oral | Oncology |
